Research
Hormonal
Adipokines such as leptin and adiponectin serve as critical biomarkers for visceral fat distribution, insulin sensitivity, and metabolic risk, with altered secretion patterns linking obesity to cardiovascular and metabolic diseases.
Your fat tissue is not just storage; it actively sends hormonal signals that affect your insulin sensitivity and heart health. Understanding this link helps explain why weight loss and metabolic health are interconnected, and why measuring certain biomarkers (like adiponectin or leptin) can provide insights into your metabolic risk beyond just weight.
GoodSupportsHIGH confidence
Adipokines are involved in the regulation of appetite and satiety, energy expenditure, activity, endothelial function, hemostasis, blood pressure, insulin sensitivity, energy metabolism in insulin sensitive tissues, adipogenesis, fat distribution and insulin secretion in pancreatic β-cells. Therefore, adipokines are clinically relevant as biomarkers for fat distribution, adipose tissue function, liver fat content, insulin sensitivity, chronic inflammation and have the potential for future pharmacological treatment strategies for obesity and its related diseases.
Why this rating
Based on a comprehensive review of multiple studies and clinical trials cited in the paper.
Source
Clinical Relevance of Adipokines
Matthias Blüher · Diabetes & Metabolism Journal · 2012
DOI 10.4093/dmj.2012.36.5.317
narrative_reviewCited 199×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- DPP-4 inhibitors lower hyperglycemia in type 2 diabetes by preventing the degradation of incretin hormones (GLP-1 and GIP), thereby potentiating glucose-dependent insulin secretion.Strong
- Exogenous leptin administration is an effective treatment for genetic leptin deficiency and lipodystrophy, but fails to significantly reduce body weight in common obesity due to central leptin resistance.Good
- Adiponectin levels are inversely correlated with visceral fat mass and insulin resistance, and low levels are associated with increased cardiovascular risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →